JP2015505843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505843A5 JP2015505843A5 JP2014546255A JP2014546255A JP2015505843A5 JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5 JP 2014546255 A JP2014546255 A JP 2014546255A JP 2014546255 A JP2014546255 A JP 2014546255A JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- biologically active
- pharmaceutical composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576034P | 2011-12-15 | 2011-12-15 | |
| US61/576,034 | 2011-12-15 | ||
| PCT/CA2012/050899 WO2013086636A1 (en) | 2011-12-15 | 2012-12-14 | Soluble igf receptor fc fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505843A JP2015505843A (ja) | 2015-02-26 |
| JP2015505843A5 true JP2015505843A5 (enExample) | 2016-02-04 |
Family
ID=48611766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546255A Pending JP2015505843A (ja) | 2011-12-15 | 2012-12-14 | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10538575B2 (enExample) |
| EP (1) | EP2791338B1 (enExample) |
| JP (1) | JP2015505843A (enExample) |
| KR (1) | KR20150031217A (enExample) |
| CN (1) | CN104066845A (enExample) |
| BR (1) | BR112014014418A2 (enExample) |
| CA (1) | CA2858389A1 (enExample) |
| HK (1) | HK1202587A1 (enExample) |
| WO (1) | WO2013086636A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| NZ732073A (en) * | 2014-12-08 | 2019-04-26 | 1Globe Biomedical Co Ltd | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
| CN107921132B (zh) * | 2015-06-04 | 2021-05-07 | 圣拉斐尔医院有限公司 | 糖尿病和igfbp3/tmem219轴抑制剂 |
| EP3302520B1 (en) * | 2015-06-04 | 2020-08-05 | Ospedale San Raffaele S.r.l. | Igfbp3 and uses thereof |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN106520806B (zh) * | 2016-11-03 | 2018-06-19 | 宜明细胞生物科技有限公司 | 一种重组car基因及其载体、car-t细胞和应用 |
| EP3632929A1 (en) | 2018-10-02 | 2020-04-08 | Ospedale San Raffaele S.r.l. | Antibodies and uses thereof |
| CN113092392B (zh) * | 2021-03-05 | 2022-11-08 | 苏州西山中科药物研究开发有限公司 | 一种检测猴血清中靶向可溶性蛋白的单克隆抗体药物总浓度的通用型方法 |
| CN119708266B (zh) * | 2025-02-26 | 2025-06-06 | 首玺(广州)医疗科技有限责任公司 | 一种胰岛素样生长因子-1连接多肽及其在子宫内膜损伤修复中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500654A (ja) | 1995-11-14 | 2000-01-25 | トーマス・ジェファーソン・ユニバーシティ | 可溶性ｉｇｆ−１受容体による腫瘍成長に対する誘導耐性 |
| DK1699822T3 (da) * | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| CN101443357A (zh) * | 2005-08-12 | 2009-05-27 | 先灵公司 | Mcp1融合物 |
| TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
| GB0702888D0 (en) | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| JP2010518140A (ja) * | 2007-02-14 | 2010-05-27 | グラクソ グループ リミテッド | Ｉｇｆ−１ｒに対する新規抗体 |
| EP2129397B1 (en) | 2007-03-02 | 2018-10-31 | Amgen, Inc. | Methods and compositions for treating tumor diseases |
| CA2694055A1 (en) | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| CA2729810A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | Tgf-.beta. antagonist multi-target binding proteins |
| US20110152173A1 (en) | 2008-07-02 | 2011-06-23 | Emergent Product Development Seattle ,LLC | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| WO2010012088A1 (en) | 2008-07-29 | 2010-02-04 | The Royal Institution For The Advancement Of Learning/Mcgill University | Apparatus and method for loading and transporting containers |
| ES2582603T5 (es) | 2008-10-01 | 2022-12-02 | Amgen Res Munich Gmbh | Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular |
| JP2012527875A (ja) * | 2009-05-28 | 2012-11-12 | グラクソ グループ リミテッド | 抗原結合タンパク質 |
-
2012
- 2012-12-14 KR KR20147019486A patent/KR20150031217A/ko not_active Withdrawn
- 2012-12-14 WO PCT/CA2012/050899 patent/WO2013086636A1/en not_active Ceased
- 2012-12-14 EP EP12857915.8A patent/EP2791338B1/en active Active
- 2012-12-14 HK HK15103272.6A patent/HK1202587A1/xx unknown
- 2012-12-14 JP JP2014546255A patent/JP2015505843A/ja active Pending
- 2012-12-14 CN CN201280067765.6A patent/CN104066845A/zh active Pending
- 2012-12-14 CA CA2858389A patent/CA2858389A1/en not_active Abandoned
- 2012-12-14 BR BR112014014418A patent/BR112014014418A2/pt not_active IP Right Cessation
- 2012-12-14 US US14/365,250 patent/US10538575B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505843A5 (enExample) | ||
| Corre et al. | The osteosarcoma microenvironment: a complex but targetable ecosystem | |
| Qazi et al. | Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma | |
| Li et al. | Tumor microenvironment in treatment of glioma | |
| Feldman | Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments | |
| JP6857498B2 (ja) | 癌を処置するための併用方法 | |
| Yu et al. | Potential approaches to the treatment of Ewing's sarcoma | |
| JP2015529641A5 (enExample) | ||
| JP2018521135A5 (enExample) | ||
| CN112867503A (zh) | 掩蔽的细胞因子缀合物 | |
| JP2017171685A5 (enExample) | ||
| EA200701250A1 (ru) | Иммуноконъюгаты против интегрина, способы и варианты применения | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JP2016535009A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2017534259A5 (enExample) | ||
| US20220056450A1 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
| JP2019506862A5 (enExample) | ||
| JP2013511559A5 (enExample) | ||
| JP2014523398A5 (enExample) | ||
| JP2018509423A5 (enExample) | ||
| JP2014525412A5 (enExample) | ||
| CN106924260B (zh) | 化合物在制备用于治疗脑胶质瘤的药物中的用途 | |
| de Oliveira Silva et al. | New avenues for the treatment of immunotherapy-resistant pancreatic cancer | |
| Schneider et al. | Use of HER2-specific chimeric antigen receptor-modified virus-specific T cells as a potential therapeutic for progressive HER2-positive glioblastoma |